Conversation
New disorder entry for Raynaud Disease (MONDO:0008364) with: - 5 pathophysiology mechanisms (VSMC/α2C-AR signaling, endothelial dysfunction, sympathetic dysregulation, platelet abnormalities, oxidative stress) - 5 phenotypes with HPO terms - 3 environmental factors (cold, stress, estrogen) - 6 treatments with MAXO terms - 8 ontology-bound terms (CL, GO, UBERON) - Evidence from 9 unique references with exact snippets - 98% compliance (100% weighted) Deep research performed via falcon provider. Co-Authored-By: Claude Opus 4.6 <noreply@anthropic.com>
|
Claude finished @kevinschaper's task in 1m 49s —— View job PR Review: Raynaud Disease EntryExcellent work on this comprehensive Raynaud Disease curation! This entry demonstrates high-quality evidence-backed pathophysiology with proper ontology term usage and well-sourced clinical information. Here are my detailed findings: Review Checklist
Strengths1. Biological and Clinical Accuracy ✅The pathophysiology mechanisms are scientifically accurate and well-structured:
2. Evidence Quality ✅All evidence items follow best practices:
3. Ontology Term Usage ✅Proper ontology term mappings throughout:
4. Clinical Completeness ✅
Minor Suggestions1. Evidence Snippet Quality (Line 224-227)The oxidative stress mechanism evidence is somewhat weak: evidence:
- reference: PMID:24418302
supports: SUPPORT
snippet: "recent advances in our understanding of the pathophysiology have highlighted
novel potential therapeutic targets"
explanation: Prete et al. review discusses pathogenic mechanisms including oxidative
stress in RP pathophysiology.Issue: The snippet doesn't explicitly mention oxidative stress or ROS. While the explanation claims the review discusses oxidative stress, the quoted text is too generic. Recommendation: Either find a more specific quote from this paper that explicitly mentions oxidative stress/ROS, or add an additional reference with a direct oxidative stress quote. This isn't critical since the mechanism is well-established, but more explicit evidence would strengthen this section. 2. Phenotype: Acrocyanosis Description (Lines 258-275)The evidence snippet (line 272-274) discusses pallor and erythema but not cyanosis explicitly: snippet: "Pallor indicates reduced blood flow due to oxygen deprivation, while
erythema appears as reperfusion."Recommendation: This snippet doesn't directly support "Acrocyanosis" as stated. Consider using the snippet from line 248-250 instead, which explicitly describes the triphasic change including cyanosis, or find a reference that specifically mentions the cyanotic phase. 3. Disease Description Clarity (Lines 14-25)The description mixes primary and secondary RP information. Consider minor restructuring for clarity:
Recommendation: Consider adding a transition like "While this entry focuses on primary Raynaud disease..." or grouping the secondary RP sentence with the subtype section below. Conformance with Guidelines ✅All CLAUDE.md requirements met:
Compliance AssessmentBased on the PR description showing 98% global compliance, 100% weighted compliance, this entry exceeds the knowledge base standards. The file includes:
Final RecommendationAPPROVE with minor optional improvements This is high-quality curation work that demonstrates:
The three suggestions above are minor enhancements rather than blocking issues. The entry is publication-ready as-is, but addressing the oxidative stress evidence and acrocyanosis snippet would make it even stronger. Great work leveraging the falcon deep research provider and maintaining rigorous evidence standards! This entry will be a valuable addition to the dismech knowledge base. |
kb/disorders/Raynaud_Disease.yaml
Outdated
| RP but not primary RP." | ||
| explanation: Structural vascular changes explain complications in secondary RP. | ||
| pathophysiology: | ||
| - name: Vascular Smooth Muscle Hyperreactivity and Alpha-2C Adrenoceptor Signaling |
There was a problem hiding this comment.
Debundled into three focused entries with downstream edges:
- Alpha-2C Adrenoceptor Cold-Induced Vasoconstriction — core ADRA2C-mediated vasospasm mechanism (includes
gene: ADRA2Cwithhgnc:283) - RhoA/ROCK Potentiation of Vasospasm — amplification via RhoA/ROCK signaling
- Estrogen Potentiation of Alpha-2C-AR — sex-based incidence difference (includes
chemical_entities: CHEBI:50114 estrogen)
Downstream edge: entry 1 → entry 2.
kb/disorders/Raynaud_Disease.yaml
Outdated
| - name: Vascular Smooth Muscle Hyperreactivity and Alpha-2C Adrenoceptor Signaling | ||
| description: > | ||
| Exaggerated vasoconstriction of digital arteries and arterioles in response to cold | ||
| or sympathetic stimulation. Cold triggers alpha-2C adrenoceptor (ADRA2C) activation |
There was a problem hiding this comment.
Added gene descriptor to the debundled Alpha-2C-AR entry:
gene:
preferred_term: ADRA2C
term:
id: hgnc:283
label: ADRA2C
| and erythema (reperfusion). This is the defining clinical feature. | ||
| phenotype_term: | ||
| preferred_term: Raynaud phenomenon | ||
| term: |
There was a problem hiding this comment.
note for @matentzn this is a good example for the HP/Mondo equiv project
| snippet: "Pallor indicates reduced blood flow due to oxygen deprivation" | ||
| explanation: Digital pallor reflects ischemia from vasospasm-induced blood flow reduction. | ||
| environmental: | ||
| - name: Cold Exposure |
There was a problem hiding this comment.
Added exposure_term:
exposure_term:
preferred_term: exposure to decreased temperature
term:
id: ECTO:0001057
label: exposure to decreased temperature
kb/disorders/Raynaud_Disease.yaml
Outdated
| snippet: "recurrent episodes of digital vasospasm triggered by exposure to | ||
| physical/chemical or emotional stress" | ||
| explanation: Emotional stress is a recognized trigger alongside physical stimuli. | ||
| - name: Female Sex Hormones |
There was a problem hiding this comment.
include CHEBI
also generally need a better way of including nodes like this which are valid but not environmental in the same way as eg exposure to cold
There was a problem hiding this comment.
Added ECTO exposure term (which links to CHEBI:50114 estrogen via its definition):
exposure_term:
preferred_term: exposure to estrogens
term:
id: ECTO:9000010
label: exposure to estrogensThere was a problem hiding this comment.
@dragon-ai-agent please make a separate issue for how to handle this in the general case. This is not an actual exposure but normal chemical level change within the body.
@kevinschaper I think it's better just not to have an ECTO term here for now - defer to @diatomsRcool
There was a problem hiding this comment.
I removed the estrogen exposure section, it seems like estrogen is covered in pathophysiology just fine
| Sildenafil and tadalafil improve digital blood flow by inhibiting PDE5, increasing | ||
| cGMP levels, and enhancing nitric oxide-mediated vasodilation. Used as second-line | ||
| therapy for refractory cases or when CCBs are insufficient. | ||
| treatment_term: |
There was a problem hiding this comment.
Added therapeutic_agent with CHEBI terms to all four pharmacotherapy treatments:
- CCBs: nifedipine (
CHEBI:7565), amlodipine (CHEBI:2668) - PDE5 inhibitors: sildenafil (
CHEBI:9139), tadalafil (CHEBI:71940) - Prostacyclin analogues: iloprost (
CHEBI:63916) - Endothelin receptor antagonists: bosentan (
CHEBI:51450)
cmungall
left a comment
cmungall
left a comment
There was a problem hiding this comment.
debundle pathophys; also some other optional suggestions
- Debundle pathophysiology into 3 focused entries with downstream edges: Alpha-2C-AR vasoconstriction, RhoA/ROCK potentiation, estrogen potentiation - Add ADRA2C gene (hgnc:283) and estrogen chemical entity (CHEBI:50114) - Add ECTO exposure terms: cold (ECTO:0001057), estrogen (ECTO:9000010) - Post-compose treatments with CHEBI drug terms: nifedipine, amlodipine, sildenafil, tadalafil, iloprost, bosentan - Re-render HTML page Co-Authored-By: Claude Opus 4.6 <noreply@anthropic.com>
# Conflicts: # cache/ecto/terms.csv # cache/enums/exposureterm_7269e022a149.csv
|
Claude finished @kevinschaper's task in 2m 47s —— View job PR Review: Raynaud Disease EntryComprehensive review completed for biological validity, guideline conformance, and completeness. Review Checklist
Verification of Previous Review CommentsAll 5 requested changes from @cmungall have been successfully addressed:
Biological and Clinical Accuracy ✅Pathophysiology MechanismsThe 7 pathophysiology mechanisms are scientifically accurate and well-structured: 1. Alpha-2C Adrenoceptor Cold-Induced Vasoconstriction (lines 62-108)
2. RhoA/ROCK Potentiation (lines 109-124)
3. Estrogen Potentiation (lines 125-142)
4. Endothelial Dysfunction (lines 143-179)
5. Sympathetic Dysregulation (lines 180-207)
6. Platelet Abnormalities (lines 208-240)
7. Oxidative Stress (lines 241-258)
Evidence Quality ✅ (with one minor note)Snippet Accuracy: Verified exact matches against abstracts for:
Evidence Source Tagging: Proper use of Support Classification: All evidence items appropriately classified (mostly SUPPORT, one PARTIAL for sympathectomy line 548) snippet: "recent advances in our understanding of the pathophysiology have highlighted
novel potential therapeutic targets"
explanation: Prete et al. review discusses pathogenic mechanisms including oxidative
stress in RP pathophysiology.The snippet is too generic and doesn't explicitly mention oxidative stress. The explanation claims the review discusses oxidative stress, but the quoted text doesn't demonstrate this. Consider finding a more specific quote from this paper or adding a supplementary reference. Ontology Term Usage ✅Excellent ontology term coverage throughout: Cell Types (CL):
Biological Processes (GO):
Phenotypes (HPO):
Anatomical Locations (UBERON):
Exposures (ECTO):
Treatments (MAXO):
Therapeutic Agents (CHEBI):
Phenotype Assessment ✅ (with one minor note)5 phenotypes with appropriate frequency annotations:
Treatment Recommendations ✅6 treatments with proper hierarchy and evidence:
All pharmacotherapy entries properly annotated with CHEBI terms as requested. Environmental Factors ✅3 environmental factors with proper evidence:
Completeness and Compliance ✅Entry completeness (from PR description: 98% global, 100% weighted):
Conformance with CLAUDE.md Guidelines ✅All requirements met:
Final RecommendationAPPROVE ✅ This is an exemplary disorder curation that demonstrates: Strengths:
Two Minor Suggestions (Optional):
Bottom Line: Great work on this comprehensive Raynaud Disease curation! 🎉 |
cmungall
left a comment
cmungall
left a comment
There was a problem hiding this comment.
one remaining request, for the sex hormone 'exposure'
also a general note best to avoid committing the html as high chance of downstream conflicts
|
✅ Created issue #364 to discuss how to handle endogenous chemical factors (like sex hormones) vs. actual environmental exposures in the general case. The issue outlines the modeling question and proposes several options for distinguishing:
For this PR, as @cmungall suggested, the ECTO term can be removed from the Female Sex Hormones environmental factor while we determine the best long-term modeling approach. |
Endogenous hormone levels are not an environmental exposure. The estrogen/sex difference is already captured in the Estrogen Potentiation of Alpha-2C-AR pathophysiology entry. Co-Authored-By: Claude Opus 4.6 <noreply@anthropic.com>
|
Claude finished @kevinschaper's task in 1m 7s —— View job PR Review: Raynaud Disease EntryTasks
CI Status ✅Build and test: passed Changes Since Last ReviewThis review covers the updated state after removing the Female Sex Hormones environmental factor (addressing cmungall's last request). The entry now has 2 environmental factors (Cold Exposure, Emotional Stress) instead of 3. Blocking Issues1. HTML page committed (per cmungall's request)
|
Co-Authored-By: Claude Opus 4.6 <noreply@anthropic.com>
|
Claude finished @kevinschaper's task in 1m 18s —— View job PR Review: Raynaud Disease EntryTasks
CI Status ✅Build and test: passed Summary of Changes Since Last ReviewThis review covers the current state of the branch. Per the commit history, the HTML page ( Issues Carried ForwardTwo non-blocking evidence quality issues identified in prior reviews remain unaddressed. They are documented here for completeness: 1. Oxidative Stress evidence snippet is unsupported
|
2 participants
Summary
Validation
Test plan
just validate kb/disorders/Raynaud_Disease.yamlpassesjust compliance kb/disorders/Raynaud_Disease.yamlshows high compliance🤖 Generated with Claude Code